Non-Hodgkin Lymphoma (NHL) Therapeutics Market to Witness Healthy Growth in Coming Years
Increasing prevalence of Non-Hodgkin’s lymphomas (NHL) and
other types of cancers to drive global Non-Hodgkin Lymphoma (NHL) therapeutics
market
According to
TechSci Research report, “Global Non-Hodgkin
Lymphoma (NHL) Therapeutics Market By Type of Therapy (Chemotherapy,
Immunotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant,
Others), By Cell Type (B-cell Lymphomas, T-cell Lymphoma), By Drug Type
(Opdivo, Adcetris, Rituxan, Imbruvica, Revlimid, Keytruda, Other Drugs), By Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By
Region, Forecast & Opportunities, 2025”, the market
is predicted to grow at a significant CAGR during the forecast period. The
global Non-Hodgkin Lymphoma (NHL) therapeutics market is primarily driven by
growing prevalence of Non-Hodgkin’s lymphomas (NHL) and other types of cancers
around the world coupled with increasing expenditure on medical and healthcare
infrastructure. Also, increasing awareness towards the effects of Non-Hodgkin’s
lymphomas (NHL) and extensive R&D activities are acting as some other major
drivers for this market. In addition to this, factors like FDA's approval for
chronic lymphocytic leukemia therapy drugs and increasing demand for innovative
drugs and novel technologies are expected to drive the market growth through
2025.
Moreover, patent expiry of standard drugs, especially
in untapped markets is anticipated to provide profitable growth opportunities
for this market in near future. Apart from this, improved diagnostic techniques
to detect NHL is fueling the growth of global Non-Hodgkin Lymphoma (NHL)
therapeutics market. However, the market is also susceptible to to some
restraints. High cost of NHL drugs and stringent regulatory guidelines is
anticipated to limit the market growth. Furthermore, various complications
associated with NHL drugs are expected to hamper the global Non-Hodgkin
Lymphoma (NHL) therapeutics market growth in coming years.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "Global Non-Hodgkin Lymphoma (NHL)
Therapeutics Market"
https://www.techsciresearch.com/report/non-hodgkin-lymphoma-nhl-therapeutics-market/5113.html
The global Non-Hodgkin
Lymphoma (NHL) therapeutics market is segmented based on type of therapy, cell
type, drug type, distribution channel and region. Based on type of therapy, the
market can be segmented into chemotherapy, immunotherapy, targeted therapy,
radiation therapy, stem cell transplant and others. Among these, radiation
therapy segment is predicted to register fastest growth in terms of revenue
during the forecast period as this therapy is used in early stages of non-Hodgkin
lymphoma (NHL). Also, in case of advanced lymphomas, radiation therapy is used
along with chemotherapy as this therapy is good at destroying non-Hodgkin
disease cells.
Regionally,
North America dominated global Non-Hodgkin
Lymphoma (NHL) therapeutics market in 2018. High prevalence of Non-Hodgkin
lymphoma (NHL) in the region and efforts by leading pharmaceutical companies to
develop efficient treatment options is further expected to aid the market
growth in North America during the forecast period. However, Asia-Pacific is
anticipated to undergo fastest growth through 2025 due to improving healthcare
reimbursement policies and increasing prevalence of Non-Hodgkin lymphoma (NHL).
Major players operating in the global
Non-Hodgkin Lymphoma (NHL) therapeutics market include AstraZeneca PLC, Baxter
International Inc., Bayer AG, Novartis AG, Eli Lilly and Company., Spectrum
Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers
Squibb Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., F. Hoffmann-La
Roche Ltd, CELGENE CORPORATION (Bristol Myers Squibb Company), Merck & Co.,
Inc., Kyowa Kirin Co., Ltd. and AbbVie Inc. The market is highly competitive
and key market players are investing on R&D activities to introduce new and
more effective products in global market.
Download
Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=5113
Customers can
also request for 10% free customization on this report.
“Extensive
R&D activities is the most important tool for the growth of Non-Hodgkin
Lymphoma (NHL) therapeutics market, which is why, large number of
pharmaceutical companies are engaged in these activities to develop innovative
formulations. Also, availability of the biosimilars at a reduced price is leading
to high growth in global Non-Hodgkin Lymphoma (NHL) therapeutics market,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
global management consulting firm.
“Global Non-Hodgkin Lymphoma (NHL)
Therapeutics Market By Type of Therapy (Chemotherapy, Immunotherapy, Targeted
Therapy, Radiation Therapy, Stem Cell Transplant, Others), By Cell Type (B-cell
Lymphomas, T-cell Lymphoma), By Drug Type (Opdivo, Adcetris, Rituxan,
Imbruvica, Revlimid, Keytruda, Other Drugs), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Forecast
& Opportunities, 2025” has evaluated
the future growth potential of global Non-Hodgkin Lymphoma (NHL) therapeutics market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global Non-Hodgkin Lymphoma (NHL) therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]